Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

US FDA issues warning on Schering's MS drug Campath

Dec 1, 2005 | AFX The US Food and Drug Administration has issued a warning on the use of Schering AG's multiple sclerosis drug Campath.

The FDA said three patients in a clinical study on the drug developed severe idiopathic thrombocytopenic purpura (ITP), a rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding.

One of the patients died, the FDA said.

Campath is so far not approved to treat MS. It is only approved for treating a form of blood cancer called B-cell chronic lymphocytic leukemia (B-CLL).

The label for Campath has a warning about serious and rare blood problems that may occur with the use of this medicine.

Schering could not be reached for comment.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo